Table 2. Risk Model for Organ Support–Free Days Used in Risk-Based Heterogeneity of Treatment Effect Analysis.
| Model variablea | Risk model coefficients | |
|---|---|---|
| Odds ratio (95% CI)b | Log odds ratioc | |
| Age, per 10 y | 0.73 (0.68-0.77) | −0.32 |
| Female sex | 1.29 (1.10-1.51) | 0.25 |
| Body mass index, per 5 units | 0.92 (0.88-0.97) | −0.08 |
| Diabetes | 0.78 (0.67-0.91) | −0.25 |
| Immunosuppressive disease or therapyd | 0.58 (0.44-0.77) | −0.54 |
| Baseline organ support | ||
| Vasopressor requirement | 0.49 (0.35-0.70) | −0.71 |
| High-flow nasal oxygen | 0.07 (0.05-0.08) | −2.70 |
| Noninvasive ventilation | 0.05 (0.04-0.06) | −3.10 |
| Invasive mechanical ventilation | 0.04 (0.03-0.05) | −3.29 |
| Neutrophil count, per 5 × 109/L | 0.74 (0.68-0.81) | −0.30 |
| Lymphocyte count, per 5 × 109/L | 1.35 (1.10-1.66) | 0.30 |
| Platelet count, per 25 × 109/L | 1.07 (1.04-1.09) | 0.06 |
Unadjusted for treatment assignment, and no statistical interactions between model variables were specified in the risk model.
Confidence intervals are reported because the internally derived risk scores were derived from a frequentist ordinal logistic model.
The log odds ratio is used to compute the risk score components.
Immunosuppressive disease or therapy was defined as concurrently having any of the following conditions: HIV, leukemia, metastatic cancer, myeloma, lupus, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, Crohn disease, granulomatosis with polyangiitis, sarcoidosis, monoclonal gammopathy of unknown significance, ankylosing spondylitis, and psoriasis; or as receiving chemotherapy or radiation, transplant, or high-dose or long-term steroid treatment.